JP2008533072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008533072A5 JP2008533072A5 JP2008501208A JP2008501208A JP2008533072A5 JP 2008533072 A5 JP2008533072 A5 JP 2008533072A5 JP 2008501208 A JP2008501208 A JP 2008501208A JP 2008501208 A JP2008501208 A JP 2008501208A JP 2008533072 A5 JP2008533072 A5 JP 2008533072A5
- Authority
- JP
- Japan
- Prior art keywords
- glycopyrrolate
- medicament
- physiologically acceptable
- leukotriene inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 15
- 229940015042 glycopyrrolate Drugs 0.000 claims 14
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 6
- 239000000812 cholinergic antagonist Substances 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 4
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical group CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 229960005127 montelukast Drugs 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 201000009240 nasopharyngitis Diseases 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 2
- 229960004764 zafirlukast Drugs 0.000 claims 2
- PZIFPMYXXCAOCC-JWQCQUIFSA-N (2s,3r)-3-(2-carboxyethylsulfanyl)-2-hydroxy-3-[2-(8-phenyloctyl)phenyl]propanoic acid Chemical compound OC(=O)CCS[C@@H]([C@@H](O)C(O)=O)C1=CC=CC=C1CCCCCCCCC1=CC=CC=C1 PZIFPMYXXCAOCC-JWQCQUIFSA-N 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229960004583 pranlukast Drugs 0.000 claims 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66191805P | 2005-03-16 | 2005-03-16 | |
| US60/661,918 | 2005-03-16 | ||
| PCT/EP2006/002247 WO2006097250A1 (en) | 2005-03-16 | 2006-03-10 | The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008533072A JP2008533072A (ja) | 2008-08-21 |
| JP2008533072A5 true JP2008533072A5 (https=) | 2009-03-12 |
| JP4991693B2 JP4991693B2 (ja) | 2012-08-01 |
Family
ID=36570797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008501208A Expired - Fee Related JP4991693B2 (ja) | 2005-03-16 | 2006-03-10 | 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8268864B2 (https=) |
| EP (1) | EP1863476B1 (https=) |
| JP (1) | JP4991693B2 (https=) |
| CN (1) | CN101128196B (https=) |
| AU (1) | AU2006224842B2 (https=) |
| CA (1) | CA2595791C (https=) |
| CY (1) | CY1117571T1 (https=) |
| DK (1) | DK1863476T3 (https=) |
| ES (1) | ES2570332T3 (https=) |
| HR (1) | HRP20160373T1 (https=) |
| HU (1) | HUE027076T2 (https=) |
| MX (1) | MX2007011273A (https=) |
| NO (1) | NO340405B1 (https=) |
| NZ (1) | NZ560206A (https=) |
| PL (1) | PL1863476T3 (https=) |
| RU (1) | RU2420285C2 (https=) |
| SI (1) | SI1863476T1 (https=) |
| WO (1) | WO2006097250A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050048614A1 (en) * | 2000-06-13 | 2005-03-03 | Children's Medical Center Corporation | Biosynthetic oncolytic molecules and uses therefor |
| ATE403654T1 (de) * | 2003-07-28 | 2008-08-15 | Janssen Pharmaceutica Nv | Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren |
| LT1976828T (lt) | 2005-12-29 | 2017-04-25 | Celtaxsys, Inc. | Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| ES2671874T3 (es) * | 2007-10-18 | 2018-06-11 | Rose U, Llc | Formulaciones tópicas de glicopirrolato |
| KR20100072295A (ko) * | 2007-10-25 | 2010-06-30 | 머크 프로스트 캐나다 리미티드 | 병용 요법 |
| AU2010258751A1 (en) * | 2009-06-09 | 2012-02-02 | Sunovion Respiratory Development Inc. | Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration |
| US9378456B2 (en) * | 2012-11-19 | 2016-06-28 | Microsoft Technology Licensing, Llc | Task completion |
| US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
| JP6114841B2 (ja) | 2013-02-28 | 2017-04-12 | ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． | グリコピロレート塩 |
| US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
| AU2014249168B2 (en) | 2013-03-12 | 2018-07-12 | Celltaxis, Llc | Methods of inhibiting leukotriene A4 hydrolase |
| CA2906035A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| EP3091959A4 (en) * | 2014-01-10 | 2017-09-20 | Dignity Sciences Limited | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same |
| ES3014615T3 (en) | 2018-05-31 | 2025-04-23 | Celltaxis Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| MA54707A (fr) * | 2019-01-10 | 2021-11-17 | Jiangyin Mucocare Pharmaceutical Co Ltd | Nouvelles formulations contenant des antagonistes des récepteurs des leucotriènes |
| BR112022015199A2 (pt) * | 2020-02-03 | 2022-10-11 | Taro Pharma Ind | Formulações tópicas de montelucaste |
| CN115792229B (zh) * | 2022-01-28 | 2024-06-18 | 华中科技大学同济医学院附属同济医院 | 鼻分泌物中tPA在制备鼻息肉及其预后检测剂中的应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0435038A (ja) * | 1990-05-31 | 1992-02-05 | Oki Electric Ind Co Ltd | 半導体素子及びその製造方法 |
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| WO1998000016A1 (en) | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| CN100391942C (zh) * | 1996-11-11 | 2008-06-04 | 索佛特克两合公司 | 对映异构纯的碱性芳基-环烷基-羟基羧酸酯,其制备方法及其在药品中的应用 |
| WO1998048839A1 (en) * | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
| US6384038B1 (en) * | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| WO1999062720A1 (fr) * | 1998-05-29 | 1999-12-09 | Citizen Watch Co., Ltd. | Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation |
| JP4672143B2 (ja) | 1998-08-04 | 2011-04-20 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| PL200941B1 (pl) * | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6086914A (en) * | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| SE9903995D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| SK288031B6 (sk) * | 2000-10-31 | 2012-12-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Propellant-free liquid inhalation formulation |
| DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| PT1372608E (pt) | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| IL158776A0 (en) | 2001-05-25 | 2004-05-12 | Pfizer | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| AU2002314102A1 (en) | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| MY148466A (en) * | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| EP1369113B1 (en) * | 2002-06-06 | 2006-11-22 | CHIESI FARMACEUTICI S.p.A. | Solubilisation of drugs in HFA propellant by means of emulsions |
| US20040038958A1 (en) | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| WO2004023984A2 (en) * | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| EP1569626A1 (en) * | 2002-12-13 | 2005-09-07 | Adagit | Pharmaceutical porous particles |
| EP1452179A1 (en) * | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| WO2004084896A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| JPWO2005055999A1 (ja) | 2003-12-08 | 2007-07-05 | 日本新薬株式会社 | 抗コリン作用剤 |
| GB0411056D0 (en) * | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
-
2006
- 2006-03-10 EP EP06723360.1A patent/EP1863476B1/en not_active Expired - Lifetime
- 2006-03-10 AU AU2006224842A patent/AU2006224842B2/en not_active Ceased
- 2006-03-10 WO PCT/EP2006/002247 patent/WO2006097250A1/en not_active Ceased
- 2006-03-10 JP JP2008501208A patent/JP4991693B2/ja not_active Expired - Fee Related
- 2006-03-10 MX MX2007011273A patent/MX2007011273A/es active IP Right Grant
- 2006-03-10 HR HRP20160373TT patent/HRP20160373T1/hr unknown
- 2006-03-10 HU HUE06723360A patent/HUE027076T2/en unknown
- 2006-03-10 PL PL06723360T patent/PL1863476T3/pl unknown
- 2006-03-10 RU RU2007138270/15A patent/RU2420285C2/ru not_active Application Discontinuation
- 2006-03-10 NZ NZ560206A patent/NZ560206A/en not_active IP Right Cessation
- 2006-03-10 SI SI200632036A patent/SI1863476T1/sl unknown
- 2006-03-10 CN CN2006800061530A patent/CN101128196B/zh not_active Expired - Fee Related
- 2006-03-10 DK DK06723360.1T patent/DK1863476T3/en active
- 2006-03-10 ES ES06723360T patent/ES2570332T3/es not_active Expired - Lifetime
- 2006-03-10 CA CA2595791A patent/CA2595791C/en not_active Expired - Fee Related
- 2006-03-16 US US11/376,615 patent/US8268864B2/en not_active Expired - Fee Related
-
2007
- 2007-10-16 NO NO20075287A patent/NO340405B1/no not_active IP Right Cessation
-
2016
- 2016-04-28 CY CY20161100365T patent/CY1117571T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533072A5 (https=) | ||
| ES2762806T3 (es) | Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos | |
| US10391078B2 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| ATE330589T1 (de) | Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege | |
| JP6827948B2 (ja) | 呼吸器疾患の治療 | |
| JP2007520508A5 (https=) | ||
| JP2013531056A5 (https=) | ||
| JP2023525759A (ja) | ウイルス性呼吸器疾患を治療するために吸入されるスタチン | |
| CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
| JP2018199684A5 (https=) | ||
| CA2474479A1 (en) | Composition for inhalation | |
| CN102325532A (zh) | 用于减轻肺部炎症的左氧氟沙星吸入剂 | |
| RU2007138270A (ru) | Комбинация антихолинергетиков и антагонистов лейкотриеновых рецепторов для лечения респираторных заболеваний и фармацевтическая композиция на ее основе | |
| JP7844340B2 (ja) | 急性肺傷害の治療のための５－アミノ－２，３－ジヒドロ－１，４－フタラジンジオン | |
| CA3035528A1 (en) | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| CN106535889A (zh) | 用于治疗肺疾病的肥大细胞稳定剂 | |
| RU2008129600A (ru) | Комбинация и фармацевтический препарат для лечения воспалительных заболеваний | |
| WO2017011729A1 (en) | Combination therapies for the treatment of lung diseases | |
| UA100777C2 (ru) | Вдыхаемые частички, содержащие тиотропий | |
| RU2006132040A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| JP2007520507A5 (https=) | ||
| ES2610104T3 (es) | Aclidinio para el uso en la mejora de la calidad del sueño en pacientes con enfermedades respiratorias | |
| EA200600886A1 (ru) | Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид |